Everyday Health rolls out CancerRx app

Share this article:
Everyday Health rolls out CancerRx app
Everyday Health rolls out CancerRx app

Everyday Health's professional news source MedPage Today has launched a bedside oncology tool with long-time partner CollabRx. The CancerRx app, which hopes to push past four tumor types in the next six months, includes molecular-level information that can help doctors hone in on the information most applicable to the patient in front of them, as well as offering information about breaking news, approved drugs and ongoing clinical trials sorted by patient type.

The company rolled out the app at the American Society of Clinical Oncology (ASCO) annual meeting, which is being held in Chicago. Everyday Health will also promote CancerRx through newsletters and its reliable source of word-of-mouth recommendations.

Everyday Health's sales and marketing VP Anthony Manson describes the tool as “precision oncology” and tells MM&M that one of the reasons for developing the iOS app was because the volume of information physicians can tap into made the team feel like “it was becoming more and more difficult for a clinician to say, ‘We're on top of things.'”

The project, which was about one year in the making, was not based solely on physician empathy—Everyday Health also sounded out website users of its online tool to find out what information clinicians wanted, and how they wanted it. “They loved the notion of having a clinical-support tool where they could find the right information for the right patient,” Manson said.

The app, which is free to physicians, also gives pharmaceutical companies the chance to engage with clinicians. Manson says the app was designed to include precision-based advertising, in addition to allowing companies to provide clinical trial data—clearly marked that it is industry supported—and new-indication push alerts that include links to approval news.

Although created with oncologists in mind, the expectation is that support staff will use it—and probably patients, too, since doctors may just turn around the handheld to share the information they've found. “Patients are pro-sumers anyway,” VP, Global Editorial Director, Ivan Oransky explained, adding that being able to pull up so much information “literally in your hand” can help doctors and patients decide what to do next, based on the most up-to-date information.

Share this article:
You must be a registered member of MMM to post a comment.


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...